Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 13 entries
Sorted by: Best Match Show Resources per page
Progestin-related WHO grade II meningiomas behavior-a single-institution comparative case series.

Neurosurgical review

Devalckeneer A, Aboukais R, Faisant M, Bourgeois P, Quentin VM, Maurage CA, Escande F, Lejeune JP.
PMID: 34850321
Neurosurg Rev. 2021 Nov 30; doi: 10.1007/s10143-021-01708-w. Epub 2021 Nov 30.

WHO grade II progestin-related meningiomas have been reported in recent series but we found no previous study describing their long-term outcome. Our study aimed to evaluate patients operated on for high-grade intracranial meningioma and who underwent long-term exposure to...

Cite
Devalckeneer A, Aboukais R, Faisant M, et al. Progestin-related WHO grade II meningiomas behavior-a single-institution comparative case series. Neurosurg Rev. 2021;doi: 10.1007/s10143-021-01708-w.
Devalckeneer, A., Aboukais, R., Faisant, M., Bourgeois, P., Quentin, V. M., Maurage, C. A., Escande, F., & Lejeune, J. P. (2021). Progestin-related WHO grade II meningiomas behavior-a single-institution comparative case series. Neurosurgical review, . https://doi.org/10.1007/s10143-021-01708-w
Devalckeneer, Antoine, et al. "Progestin-related WHO grade II meningiomas behavior-a single-institution comparative case series." Neurosurgical review vol. (2021). doi: https://doi.org/10.1007/s10143-021-01708-w
Devalckeneer A, Aboukais R, Faisant M, Bourgeois P, Quentin VM, Maurage CA, Escande F, Lejeune JP. Progestin-related WHO grade II meningiomas behavior-a single-institution comparative case series. Neurosurg Rev. 2021 Nov 30; doi: 10.1007/s10143-021-01708-w. Epub 2021 Nov 30. PMID: 34850321.
Copy Download .nbib Format: NLM
Estrogen and Progesterone Therapy and Meningiomas.

Endocrinology

Hage M, Plesa O, Lemaire I, Raffin Sanson ML.
PMID: 34935947
Endocrinology. 2021 Dec 22; doi: 10.1210/endocr/bqab259. Epub 2021 Dec 22.

Meningiomas are common intracranial tumors with female predominance. Their etiology is still poorly documented. The role of sexual hormones has long been evoked, and data have been conflicting across studies. However, a dose-dependent relationship between the incidence and growth...

Cite
Hage M, Plesa O, Lemaire I, et al. Estrogen and Progesterone Therapy and Meningiomas. Endocrinology. 2021;doi: 10.1210/endocr/bqab259.
Hage, M., Plesa, O., Lemaire, I., & Raffin Sanson, M. L. (2021). Estrogen and Progesterone Therapy and Meningiomas. Endocrinology, . https://doi.org/10.1210/endocr/bqab259
Hage, Mirella, et al. "Estrogen and Progesterone Therapy and Meningiomas." Endocrinology vol. (2021). doi: https://doi.org/10.1210/endocr/bqab259
Hage M, Plesa O, Lemaire I, Raffin Sanson ML. Estrogen and Progesterone Therapy and Meningiomas. Endocrinology. 2021 Dec 22; doi: 10.1210/endocr/bqab259. Epub 2021 Dec 22. PMID: 34935947.
Copy Download .nbib Format: NLM
The effects of chlormadinone acetate on lower urinary tract symptoms and erectile functions of patients with benign prostatic hyperplasia: a prospective multicenter clinical study.

Advances in urology

Fujimoto K, Hirao Y, Ohashi Y, Shibata Y, Fuji K, Tsuji H, Miyazawa K, Ohtani M, Furuya R, Boku E.
PMID: 23762042
Adv Urol. 2013;2013:584678. doi: 10.1155/2013/584678. Epub 2013 May 16.

Purpose. To evaluate the effects of chlormadinone acetate (CMA), progesterone-derived antiandrogen, on lower urinary tract symptoms (LUTS) and erectile functions of benign prostatic hyperplasia (BPH). Methods. A multicenter, single-cohort prospective study was conducted. A total of 114 patients received...

Cite
Fujimoto K, Hirao Y, Ohashi Y, et al. The effects of chlormadinone acetate on lower urinary tract symptoms and erectile functions of patients with benign prostatic hyperplasia: a prospective multicenter clinical study. Adv Urol. 2013;2013:584678doi: 10.1155/2013/584678.
Fujimoto, K., Hirao, Y., Ohashi, Y., Shibata, Y., Fuji, K., Tsuji, H., Miyazawa, K., Ohtani, M., Furuya, R., & Boku, E. (2013). The effects of chlormadinone acetate on lower urinary tract symptoms and erectile functions of patients with benign prostatic hyperplasia: a prospective multicenter clinical study. Advances in urology, 2013584678. https://doi.org/10.1155/2013/584678
Fujimoto, Kiyohide, et al. "The effects of chlormadinone acetate on lower urinary tract symptoms and erectile functions of patients with benign prostatic hyperplasia: a prospective multicenter clinical study." Advances in urology vol. 2013 (2013): 584678. doi: https://doi.org/10.1155/2013/584678
Fujimoto K, Hirao Y, Ohashi Y, Shibata Y, Fuji K, Tsuji H, Miyazawa K, Ohtani M, Furuya R, Boku E. The effects of chlormadinone acetate on lower urinary tract symptoms and erectile functions of patients with benign prostatic hyperplasia: a prospective multicenter clinical study. Adv Urol. 2013;2013:584678. doi: 10.1155/2013/584678. Epub 2013 May 16. PMID: 23762042; PMCID: PMC3671298.
Copy Download .nbib Format: NLM
A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study.

Japanese journal of clinical oncology

Sugimoto M, Kakehi Y, Horie S, Hirao Y, Akaza H.
PMID: 34698353
Jpn J Clin Oncol. 2021 Oct 26; doi: 10.1093/jjco/hyab162. Epub 2021 Oct 26.

OBJECTIVES: This study was conducted to evaluate the effect of low-dose chlormadinone acetate, an antiandrogen agent, on the persistence rate of active surveillance in patients with low-risk prostate cancer.METHODS: The study was a multicenter, placebo-controlled, double-blind, randomized controlled trial...

Cite
Sugimoto M, Kakehi Y, Horie S, et al. A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study. Jpn J Clin Oncol. 2021;doi: 10.1093/jjco/hyab162.
Sugimoto, M., Kakehi, Y., Horie, S., Hirao, Y., & Akaza, H. (2021). A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study. Japanese journal of clinical oncology, . https://doi.org/10.1093/jjco/hyab162
Sugimoto, Mikio, et al. "A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study." Japanese journal of clinical oncology vol. (2021). doi: https://doi.org/10.1093/jjco/hyab162
Sugimoto M, Kakehi Y, Horie S, Hirao Y, Akaza H. A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study. Jpn J Clin Oncol. 2021 Oct 26; doi: 10.1093/jjco/hyab162. Epub 2021 Oct 26. PMID: 34698353.
Copy Download .nbib Format: NLM
Chlormadinone acetate is effective for hot flush during androgen deprivation therapy.

Prostate international

Koike H, Morikawa Y, Matsui H, Shibata Y, Ito K, Suzuki K.
PMID: 24223412
Prostate Int. 2013;1(3):113-6. doi: 10.12954/PI.12010. Epub 2013 Sep 27.

PURPOSE: To investigate the clinical efficacy of low-dose chlormadinone acetate (CMA) in prostate cancer patients who suffer from hot flushes that is a major side effect of androgen deprivation therapy.METHODS: Our study included 32 prostate cancer patients who had...

Cite
Koike H, Morikawa Y, Matsui H, et al. Chlormadinone acetate is effective for hot flush during androgen deprivation therapy. Prostate Int. 2013;1(3):113-6doi: 10.12954/PI.12010.
Koike, H., Morikawa, Y., Matsui, H., Shibata, Y., Ito, K., & Suzuki, K. (2013). Chlormadinone acetate is effective for hot flush during androgen deprivation therapy. Prostate international, 1(3), 113-6. https://doi.org/10.12954/PI.12010
Koike, Hidekazu, et al. "Chlormadinone acetate is effective for hot flush during androgen deprivation therapy." Prostate international vol. 1,3 (2013): 113-6. doi: https://doi.org/10.12954/PI.12010
Koike H, Morikawa Y, Matsui H, Shibata Y, Ito K, Suzuki K. Chlormadinone acetate is effective for hot flush during androgen deprivation therapy. Prostate Int. 2013;1(3):113-6. doi: 10.12954/PI.12010. Epub 2013 Sep 27. PMID: 24223412; PMCID: PMC3814123.
Copy Download .nbib Format: NLM
Prospective study of fertility-sparing treatment with chlormadinone acetate for endometrial carcinoma and atypical hyperplasia in young women.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

Ouasti S, Bucau M, Larouzee E, Clement De Givry S, Chabbert-Buffet N, Koskas M.
PMID: 34558063
Int J Gynaecol Obstet. 2021 Sep 24; doi: 10.1002/ijgo.13941. Epub 2021 Sep 24.

OBJECTIVE: To confirm that the efficiency of the use of chlormadinone acetate for 6 months to obtain remission of atypical hyperplasia or endometrial carcinoma is comparable to that of the use of other fertility-sparing treatments.METHOD: The present study is...

Cite
Ouasti S, Bucau M, Larouzee E, et al. Prospective study of fertility-sparing treatment with chlormadinone acetate for endometrial carcinoma and atypical hyperplasia in young women. Int J Gynaecol Obstet. 2021;doi: 10.1002/ijgo.13941.
Ouasti, S., Bucau, M., Larouzee, E., Clement De Givry, S., Chabbert-Buffet, N., & Koskas, M. (2021). Prospective study of fertility-sparing treatment with chlormadinone acetate for endometrial carcinoma and atypical hyperplasia in young women. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, . https://doi.org/10.1002/ijgo.13941
Ouasti, Samia, et al. "Prospective study of fertility-sparing treatment with chlormadinone acetate for endometrial carcinoma and atypical hyperplasia in young women." International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics vol. (2021). doi: https://doi.org/10.1002/ijgo.13941
Ouasti S, Bucau M, Larouzee E, Clement De Givry S, Chabbert-Buffet N, Koskas M. Prospective study of fertility-sparing treatment with chlormadinone acetate for endometrial carcinoma and atypical hyperplasia in young women. Int J Gynaecol Obstet. 2021 Sep 24; doi: 10.1002/ijgo.13941. Epub 2021 Sep 24. PMID: 34558063.
Copy Download .nbib Format: NLM
Antigonadotropic progestogens as contraceptive agents in women with contraindication to combined pill.

Hormone molecular biology and clinical investigation

Maitrot-Mantelet L, Agopian A, Gompel A.
PMID: 25961217
Horm Mol Biol Clin Investig. 2010 Dec 01;3(3):441-7. doi: 10.1515/HMBCI.2010.062.

Synthetic progestogens belong to different pharmacological classes and are mixed steroids. They display different properties due to their various affinities to the different steroid receptors. In addition, the dosage used can modify their side effects. Normethyltestosterone used at minimal...

Cite
Maitrot-Mantelet L, Agopian A, Gompel A. Antigonadotropic progestogens as contraceptive agents in women with contraindication to combined pill. Horm Mol Biol Clin Investig. 2010;3(3):441-7doi: 10.1515/HMBCI.2010.062.
Maitrot-Mantelet, L., Agopian, A., & Gompel, A. (2010). Antigonadotropic progestogens as contraceptive agents in women with contraindication to combined pill. Hormone molecular biology and clinical investigation, 3(3), 441-7. https://doi.org/10.1515/HMBCI.2010.062
Maitrot-Mantelet, Lorraine, et al. "Antigonadotropic progestogens as contraceptive agents in women with contraindication to combined pill." Hormone molecular biology and clinical investigation vol. 3,3 (2010): 441-7. doi: https://doi.org/10.1515/HMBCI.2010.062
Maitrot-Mantelet L, Agopian A, Gompel A. Antigonadotropic progestogens as contraceptive agents in women with contraindication to combined pill. Horm Mol Biol Clin Investig. 2010 Dec 01;3(3):441-7. doi: 10.1515/HMBCI.2010.062. PMID: 25961217.
Copy Download .nbib Format: NLM
DNA adduct formation of selected sex steroids in human liver slices in vitro.

Toxicology in vitro : an international journal published in association with BIBRA

Feser W, Kerdar RS, Baumann A, Körber J, Blode H, Kuhnz W.
PMID: 20654417
Toxicol In Vitro. 1998 Aug;12(4):353-64. doi: 10.1016/s0887-2333(98)80005-2.

We report investigations into the potential of the steroid hormones chlormadinone acetate (CMA), cyproterone acetate (CPA), dexamethasone (DEX), estradiol (E(2)), ethinylestradiol (EE(2)), gestodene (GEST), levonorgestrel (LNG), megestrol acetate (MGA), medroxy progesterone acetate (MPA), mifepristone (MIFE), norethisterone (NET), prednisolone (PRED),...

Cite
Feser W, Kerdar RS, Baumann A, et al. DNA adduct formation of selected sex steroids in human liver slices in vitro. Toxicol In Vitro. 1998;12(4):353-64doi: 10.1016/s0887-2333(98)80005-2.
Feser, W., Kerdar, R. S., Baumann, A., Körber, J., Blode, H., & Kuhnz, W. (1998). DNA adduct formation of selected sex steroids in human liver slices in vitro. Toxicology in vitro : an international journal published in association with BIBRA, 12(4), 353-64. https://doi.org/10.1016/s0887-2333(98)80005-2
Feser, W, et al. "DNA adduct formation of selected sex steroids in human liver slices in vitro." Toxicology in vitro : an international journal published in association with BIBRA vol. 12,4 (1998): 353-64. doi: https://doi.org/10.1016/s0887-2333(98)80005-2
Feser W, Kerdar RS, Baumann A, Körber J, Blode H, Kuhnz W. DNA adduct formation of selected sex steroids in human liver slices in vitro. Toxicol In Vitro. 1998 Aug;12(4):353-64. doi: 10.1016/s0887-2333(98)80005-2. PMID: 20654417.
Copy Download .nbib Format: NLM
A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial.

Contraception and reproductive medicine

Jaisamrarn U, Santibenchakul S.
PMID: 29662684
Contracept Reprod Med. 2018 Apr 10;3:5. doi: 10.1186/s40834-018-0058-9. eCollection 2018.

BACKGROUND: Oral contraceptives (OCs), aside from contraceptive efficacy, have been widely known for their non-contraceptive benefits. Different progestogens component of the OCs have been shown to improve the skin, hair, menstrual cycle related disorders and dysmenorrhoeic pain. Thus, we...

Cite
Jaisamrarn U, Santibenchakul S. A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial. Contracept Reprod Med. 2018;3:5doi: 10.1186/s40834-018-0058-9.
Jaisamrarn, U., & Santibenchakul, S. (2018). A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial. Contraception and reproductive medicine, 35. https://doi.org/10.1186/s40834-018-0058-9
Jaisamrarn, Unnop, and Santibenchakul, Somsook. "A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial." Contraception and reproductive medicine vol. 3 (2018): 5. doi: https://doi.org/10.1186/s40834-018-0058-9
Jaisamrarn U, Santibenchakul S. A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial. Contracept Reprod Med. 2018 Apr 10;3:5. doi: 10.1186/s40834-018-0058-9. eCollection 2018. PMID: 29662684; PMCID: PMC5891982.
Copy Download .nbib Format: NLM
Classification and pharmacology of progestins.

Maturitas

Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH.
PMID: 19434889
Maturitas. 2008 Sep-Oct;61(1):171-80. doi: 10.1016/j.maturitas.2008.11.013.

Besides the natural progestin, progesterone, there are different classes of progestins, such as retroprogesterone (i.e. dydrogesterone), progesterone derivatives (i.e. medrogestone) 17alpha-hydroxyprogesterone derivatives (i.e. chlormadinone acetate, cyproterone acetate, medroxyprogesterone acetate, megestrol acetate), 19-norprogesterone derivatives (i.e. nomegestrol, promegestone, trimegestone, nesterone), 19-nortestosterone...

Cite
Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2008;61(1):171-80doi: 10.1016/j.maturitas.2008.11.013.
Schindler, A. E., Campagnoli, C., Druckmann, R., Huber, J., Pasqualini, J. R., Schweppe, K. W., & Thijssen, J. H. (2008). Classification and pharmacology of progestins. Maturitas, 61(1), 171-80. https://doi.org/10.1016/j.maturitas.2008.11.013
Schindler, Adolf E, et al. "Classification and pharmacology of progestins." Maturitas vol. 61,1 (2008): 171-80. doi: https://doi.org/10.1016/j.maturitas.2008.11.013
Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. Maturitas. 2008 Sep-Oct;61(1):171-80. doi: 10.1016/j.maturitas.2008.11.013. PMID: 19434889.
Copy Download .nbib Format: NLM
Clinical utility of chlormadinone acetate (Lutoral™) in frozen-thawed embryo transfer with hormone replacement.

Reproductive medicine and biology

Asada Y, Hashiba Y, Hattori Y, Inoue D, Ito R, Fukunaga N, Sonohara M.
PMID: 31312109
Reprod Med Biol. 2019 May 09;18(3):290-295. doi: 10.1002/rmb2.12274. eCollection 2019 Jul.

PURPOSE: The clinical utility of chlormadinone acetate tablets (Lutoral™), an orally active progestin which has been available since June 2007, was compared to an in-house vaginal suppository formulation of progesterone used between 2006 and 2007 for assisted reproductive technology...

Cite
Asada Y, Hashiba Y, Hattori Y, et al. Clinical utility of chlormadinone acetate (Lutoral™) in frozen-thawed embryo transfer with hormone replacement. Reprod Med Biol. 2019;18(3):290-295doi: 10.1002/rmb2.12274.
Asada, Y., Hashiba, Y., Hattori, Y., Inoue, D., Ito, R., Fukunaga, N., & Sonohara, M. (2019). Clinical utility of chlormadinone acetate (Lutoral™) in frozen-thawed embryo transfer with hormone replacement. Reproductive medicine and biology, 18(3), 290-295. https://doi.org/10.1002/rmb2.12274
Asada, Yoshimasa, et al. "Clinical utility of chlormadinone acetate (Lutoral™) in frozen-thawed embryo transfer with hormone replacement." Reproductive medicine and biology vol. 18,3 (2019): 290-295. doi: https://doi.org/10.1002/rmb2.12274
Asada Y, Hashiba Y, Hattori Y, Inoue D, Ito R, Fukunaga N, Sonohara M. Clinical utility of chlormadinone acetate (Lutoral™) in frozen-thawed embryo transfer with hormone replacement. Reprod Med Biol. 2019 May 09;18(3):290-295. doi: 10.1002/rmb2.12274. eCollection 2019 Jul. PMID: 31312109; PMCID: PMC6613020.
Copy Download .nbib Format: NLM
IVF impact on the risk of recurrence of endometrial adenocarcinoma after fertility-sparing management.

Reproductive biomedicine online

Vaugon M, Peigné M, Phelippeau J, Gonthier C, Koskas M.
PMID: 34315696
Reprod Biomed Online. 2021 Sep;43(3):495-502. doi: 10.1016/j.rbmo.2021.06.007. Epub 2021 Jun 16.

RESEARCH QUESTION: Do IVF treatments after conservative management of endometrial atypical hyperplasia or grade 1 endometrial adenocarcinoma (AH/EC) increase the risk of disease recurrence?DESIGN: This is a prospective cohort study from a national registry from January 2008 to July...

Cite
Vaugon M, Peigné M, Phelippeau J, et al. IVF impact on the risk of recurrence of endometrial adenocarcinoma after fertility-sparing management. Reprod Biomed Online. 2021;43(3):495-502doi: 10.1016/j.rbmo.2021.06.007.
Vaugon, M., Peigné, M., Phelippeau, J., Gonthier, C., & Koskas, M. (2021). IVF impact on the risk of recurrence of endometrial adenocarcinoma after fertility-sparing management. Reproductive biomedicine online, 43(3), 495-502. https://doi.org/10.1016/j.rbmo.2021.06.007
Vaugon, Maïlys, et al. "IVF impact on the risk of recurrence of endometrial adenocarcinoma after fertility-sparing management." Reproductive biomedicine online vol. 43,3 (2021): 495-502. doi: https://doi.org/10.1016/j.rbmo.2021.06.007
Vaugon M, Peigné M, Phelippeau J, Gonthier C, Koskas M. IVF impact on the risk of recurrence of endometrial adenocarcinoma after fertility-sparing management. Reprod Biomed Online. 2021 Sep;43(3):495-502. doi: 10.1016/j.rbmo.2021.06.007. Epub 2021 Jun 16. PMID: 34315696.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 13 entries